Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: consequently (22), thus (80), hence (63)

PRIVACY NOTICE_Synergy between PCI with TAXUS and Cardiac SurgeryREV

Description: Synergy between PCI with TAXUS and Cardiac Surgery: SYNTAX Extended Survival (SYNTAXES) This is a privacy notice for patients who took part in the
Url: /Media/Southampton-Clinical-Research/PRIVACY-NOTICE-Synergy-between-PCI-with-TAXUS-and-Cardiac-SurgeryREV.docx

Featured research: Tackling whooping cough

Description: Auto Generated Title The NIHR Wellcome Trust Clinical Research Facility at the Southampton General Hospital is taking part in a new study, a
Url: /ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-Help-us-tackle-whooping-cough.aspx

Demand management tutorial key learning points

Description: Auto Generated Title Case 1 We are still getting many requests for TSH and FT4 in people on thyroxine for p
Url: /HealthProfessionals/BiochemistrytutorialforGPs/Tutorialarchive/Demandmanagementtutorialthree/Demandmanagementtutorialkeylearningpoints.aspx

Nursing and midwifery staffing report February 2026

Description: Report notes - Nursing and midwifery staffing hours - February 2026 Our staffing levels are continuously monitored through
Url: /Media/UHS-website-2019/Docs/About-the-Trust/performance/Nursing-and-midwifery-staffing-report.pdf

University Hospital Southampton NHS FT Audit Certificate 2024-25 - Signed 19.12.25

Description: Independent auditor’s report to the members of the Council of Governors of University Hospital Southampton NHS Foundation T
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/University-Hospital-Southampton-NHS-FT-Audit-Certificate-2024-25-Signed-19.12.25.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) –
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Quality account 24-25 final

Description: QUALITY ACCOUNT 2024/25 QUALITY ACCOUNT Contents Part 1: Statement on quality from the chief executive 1.1 Chief executive’s
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/quality-account-24-25-final1.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDA
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

UPL gender pay gap report 2024

Description: Gender Pay Gap. Our Gender Pay Gap at a Glance Snapshot from 5th April 2024 The Context This is the first yea
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UPL-gender-pay-gap-report-2024.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

101 to 110 of 344

Previous … 9 10 11 12 13 … Next